The Concept of Neoantigens Every melanoma tumor accumulates a unique set of DNA mutations. When these mutations occur in protein-coding genes, the altered proteins can be processed into short peptides - called neoantigens - and displayed on the tumor cell surface. Because neoantigens arise only in cancer cells and not in normal tissue, they should in principle be recognized and attacked by the immune system without triggering autoimmunity.
The Neoantigen Vaccine Strategy This clinical trial tested whether vaccinating melanoma patients with peptides derived from their own tumor's specific neoantigens could activate potent T cell responses. For each patient, whole-exome sequencing of their tumor was used to identify mutations, and machine learning algorithms predicted which mutated peptides would bind the patient's specific immune recognition molecules (HLA proteins).
Study Design and Patient Population Six high-risk melanoma patients (stage IIIB/C and stage IVM1b) who had undergone surgical tumor removal were enrolled. Each received a personalized vaccine consisting of up to 20 long peptides covering their individual tumor neoantigens, mixed with the immune-stimulating adjuvant poly-ICLC (Hiltonol). Vaccinations were given as five priming doses followed by two booster doses.
Clinical Outcomes At a median follow-up of 25 months, four of the six vaccinated patients showed no disease recurrence. The two patients who progressed both subsequently received pembrolizumab (anti-PD-1) and achieved complete tumor regression, a remarkable result since the expected complete response rate for first-line pembrolizumab in metastatic melanoma was only about 6%.
Whole-Exome Sequencing and Mutation Calling Clinical-grade whole-exome sequencing was performed on each patient's tumor and matched normal (germline) DNA. A computational pipeline identified somatic mutations specific to the tumor, filtering out normal genetic variation. RNA-sequencing confirmed that the mutated genes were actually expressed in the tumor.
Predicting HLA Binding The NetMHCpan algorithm was used to predict which mutated peptides would bind with high affinity to the patient's own HLA class I molecules - the proteins that present antigens to CD8 killer T cells. Neoantigen candidates with predicted binding affinity below 150 nM were prioritized, along with peptides arising from frameshift mutations that generate completely novel amino acid sequences (neoORFs).
Peptide Manufacturing and Formulation Up to 20 selected 15-30 amino acid long peptides per patient were synthesized at clinical grade and grouped into four injection pools. Each pool was mixed with 0.5 mg of poly-ICLC adjuvant on the day of vaccination and injected subcutaneously at different anatomical sites, aiming to maximize immune activation while minimizing interference between pools.
Safety Profile Treatment-related adverse events were mild and manageable, including flu-like symptoms, injection site reactions, rash, and fatigue. No serious autoimmune toxicities were observed, consistent with the theoretical advantage of targeting non-self neoantigens over shared tumor antigens that are also present on normal tissues.
CD4 T Cell Responses Dominate Vaccine-induced immune responses were measured by IFN-gamma ELISPOT assays. CD4+ helper T cell responses were detected against 60% of all immunizing peptides (58 of 97 unique neoantigens across patients), measured both directly ex vivo and after a brief in vitro expansion step. These rates far exceeded the approximately 1% neoantigen response rates typically seen after checkpoint blockade therapy alone.
CD8 T Cell Responses CD8+ cytotoxic T cell responses were detected against 16% of immunizing peptides. While this rate was lower than CD4 responses - partly because the vaccine used long peptides designed for MHC class II loading - at least one CD8 response per patient was documented in 47% of tested peptide pools, confirming that the vaccine also activated cancer-killing cytotoxic T cells.
Polyfunctionality and High Avidity More than 30% of neoantigen-reactive T cells were polyfunctional, simultaneously secreting two or three inflammatory cytokines (IFN-gamma, TNF-alpha, IL-2). Some T cell lines showed responses at peptide concentrations as low as 10 picomolar, indicating that very few peptide-MHC complexes on a target cell would be needed to trigger killing.
Specificity for Mutated Over Normal Protein In 86% of tested T cell lines, T cells preferentially recognized the mutated peptide over the corresponding normal (wildtype) sequence from the same protein. This confirms that the vaccine was stimulating responses specifically against cancer-associated neoantigens rather than potentially harmful responses against the normal protein.
Endogenous Antigen Processing Confirmed To confirm that the T cell responses were clinically meaningful and not just reactions to synthetic peptides, neoantigen-reactive T cells were tested against autologous antigen-presenting cells engineered to express the mutated proteins internally. In 73% of CD4 and 100% of CD8 T cell lines, T cells recognized endogenously processed and presented antigens, proving they could attack tumor cells that naturally produce these proteins.
Direct Tumor Cell Recognition For two patients (Patients 2 and 6), neoantigen-specific T cells directly recognized and responded to autologous melanoma cell lines grown from their own tumors, demonstrating that vaccine-induced T cells can engage actual cancer cells in vitro.
Clonal Expansion Tracked by Tetramers HLA class II tetramers loaded with neoantigen peptides were used to directly visualize and count neoantigen-specific CD4 T cells in patient blood. Tetramer-positive cells represented approximately 0.03-0.06% of all circulating CD4 T cells at week 16, a substantial frequency for an antigen-specific population in the blood.
Expanded T Cell Repertoire After PD-1 Blockade For the two patients who later received pembrolizumab, T cell responses were retested months later. Both patients showed persistence of vaccine-induced responses plus new T cell responses against additional neoantigens that were not detected before pembrolizumab treatment, suggesting that checkpoint blockade and neoantigen vaccination have synergistic effects on the breadth of anti-tumor T cell immunity.
Addressing Tumor Heterogeneity A core challenge in cancer treatment is that tumors consist of diverse cell clones, each carrying different mutations. A vaccine targeting 20 personal neoantigens can potentially activate T cells against multiple distinct cancer clones simultaneously, reducing the chance that any single clone can evade by losing one antigen.
Synergy with Checkpoint Inhibitors The two complete responses observed after pembrolizumab in vaccinated patients who had progressed suggest that pre-existing vaccine-induced T cells were re-invigorated by PD-1 blockade. This synergy model - vaccination to create a broad army of tumor-reactive T cells, then checkpoint blockade to unleash them - is a compelling framework for future combination trials.
Long Peptides Activate Both T Cell Types The use of 15-30 amino acid long peptides, rather than minimal MHC class I epitopes, enabled simultaneous activation of both CD4 and CD8 T cells because long peptides require antigen-presenting cells to process them and present fragments on both MHC class I and class II molecules, naturally engaging the full T cell response.
Comparison to Other Immunotherapies The 60% CD4 neoantigen response rate substantially exceeds the approximately 1% spontaneous neoantigen response rates seen after checkpoint blockade or tumor-infiltrating lymphocyte therapy, establishing that a targeted personal vaccine is far more efficient at expanding the neoantigen-specific T cell repertoire than non-antigen-directed approaches.
Improving Neoantigen Prediction Only 16% of targeted neoantigens induced CD8 T cell responses despite selection by high-affinity HLA binding prediction. The authors note that better computational tools for predicting antigen presentation and T cell receptor compatibility will be needed to increase the fraction of vaccine components that generate functional T cell responses.
Class II Epitope Prediction The unexpectedly high proportion of CD4 (class II) responses compared to CD8 (class I) responses suggests that the peptide vaccine inadvertently activated class II responses that algorithms optimized for class I binding did not predict. Future vaccines could deliberately optimize for both class I and class II presentation.
Planned Combination Trials Based on these results, the authors planned follow-up trials formally testing the combination of personal neoantigen vaccines with checkpoint blockade from the outset, rather than only as rescue therapy for patients who progress after vaccination alone.
Manufacturing Timelines as a Challenge The median time from surgery to vaccine administration was 18 weeks in this study. Reducing this manufacturing time is critical for patients with rapidly advancing disease, and subsequent improvements in sequencing speed, computational pipelines, and GMP peptide production have been actively pursued by the field.